Acasti Pharma is a biopharmaceutical company focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids (OM3) delivered both as free fatty acids and bound-to-phospholipid esters derived from krill oil. Co.'s primary product candidate is CaPre, an OM3 phospholipid therapeutic, which it is developing for the treatment of severe hypertriglyceridemia, a condition characterized by high or severe levels of triglycerides in the bloodstream. We show 5 historical shares outstanding datapoints in our coverage of ACST's shares outstanding history.
Understanding the changing numbers of ACST shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACST versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACST by allowing them to research ACST shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
